1 available, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow VAL-1221: new trials by email Literature Review of VAL-1221 trials Research Report on VAL-1221
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease VAL-1221, RhGAA - Pompe Disease | Phase 1 / Phase 2 | Terminated | Valerion Therapeutics, LLC | 12 | 2017-06-21 | 2020-06-02 |
| Intravenous VAL-1221 Lafora Expanded Access Protocol VAL-1221 - Lafora Disease | Available | Parasail, LLC | 2023-07-05 |
Glycogen Storage Disease (2) · Glycogen Storage Disease Type II (1) · Lafora Disease (1) · Myoclonic Epilepsies, Progressive (1)
Parasail, LLC (1) · Valerion Therapeutics, LLC (1)
United Kingdom (1) · United States (1)
Hal Landy, MD (1)